Related Experiment Video
Updated: Jul 18, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders
1Feist-Weiller Cancer Center, 1501 Kings Highway, Shreveport, LA 71103, USA. fturtu@lsuhsc.edu
Abstract:
Denileukin diftitox (Ontak) represents an example of a fused molecule that targets cells bearing high affinity interleukin-2 receptors internalized via receptor-mediated endocytosis in an acidified vesicle. Denileukin diftitox is proteolytically cleaved within the endosome liberating the enzymatically active portion of the diphtheria toxin, the A fragment. Diphtheria toxin fragment A is released into the cytosol inhibiting the protein synthesis through the ADP-ribosylation of the elongation factor-2, and leading to cell death. This review focuses on the clinical trials that led to the FDA approval of the drug for cutaneous T cell lymphoma in the US, and investigational studies demonstrating drug-activity against B and T-cell non-Hodgkin's lymphoma, chronic lymphocytic lymphoma and acute graft versus disease within allogeneic hematopoietic stem cell transplant.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

